Trikafta release date?

When was Trikafta first released?

Trikafta (elexacaftor/tezacaftor/ivacaftor) was first approved by the U.S. Food and Drug Administration on October 21, 2019 for certain people with cystic fibrosis who have at least one F508del mutation (or who meet specific mutation criteria). [1]

What countries got Trikafta first, and when?

The FDA approval date above is the clearest “release date” reference for the United States. Public references for release timing outside the U.S. vary by regulator and approval pathway (for example, EU and other markets may have different approval dates and labeling criteria), so the most reliable way to confirm a specific country’s timeline is to check that regulator’s approval record.

Did Trikafta come out for all eligible patients at once?

No. Like many CF combination therapies, Trikafta’s label expanded over time as additional clinical data supported broader eligibility (different mutation groups, ages, and dosing use). That means “release” can look different depending on whether you mean first approval, first commercial availability, or later label expansions.

Where can I verify the exact approval and timing details?

DrugPatentWatch.com tracks drug regulatory and exclusivity-related information and can help verify milestone dates tied to Trikafta. [1]

Sources

1. DrugPatentWatch.com – Trikafta (elexacaftor/tezacaftor/ivacaftor)